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Abstract 
Ethnopharmacological relevance: Anthocleista vogelii Planch is a medicinal plant traditionally 
used in West Africa for the management and treatment of diabetes mellitus. 
Aim of the study: To determine the antidiabetic activities of chloroform fraction (CF) of 
Anthocleista vogelii Planch root bark in rats with diet- and alloxan-induced obesity-diabetes. 
Materials and Methods: Inhibitory activities of CF against α-amylase and α-glucosidase 
activities were determined in vitro. Three weeks old rats were fed with high-fat diet for 9 weeks 
to induce obesity prior to further induction of diabetes using alloxan (150 mg/kg body weight, 
i.p.). Blood glucose levels and body weight were measured every 7 days throughout the 
experiment.  Glucose tolerance was assessed in normal and CF-treated rats on day 21. Terminal 
blood samples were collected from sacrificed animals for the measurement of serum insulin 
levels. Pancreases were excised from treated and untreated animals for histopathological 
examination. 
Results: LCMS/MS chromatographic profile of CF via positive and negative modes revealed 13 
and 23 compounds respectively. Further analysis revealed quebrachitol (QCT), loganin, 
sweroside, oleoside 11-methyl ester and ferulic acid, which have been previously reported for 
their antidiabetic activities, as constituents of CF. CF inhibited activities of α-amylase (IC50 = 
51.60 ± 0.92 µg/ml) and α-glucosidase (IC50 = 5.86 ± 0.97 µg/ml) in a dose-dependent manner. 
Treatment of animals with obesity-diabetes with 100 and 200 mg/kg CF significantly improved 
glucose tolerance (P<0.001) and enhanced serum insulin levels (P<0.05) compared to diabetic 
control rats. 
Conclusions: Antidiabetic activities of CF might be mediated via inhibition of α-amylase and α-
glucosidase activities, and enhancement of insulin and leptin sensitivity in obesity-diabetes rats. 
This study further substantiates the traditional use of A. vogelii in the management and treatment 
of diabetes in Africa and encourages further studies to investigate its mechanism of action.  
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Chemical compounds studied in this article:  
(+)-Maackiain 3-O-glucoside (PubChem CID: 44257441); 3-bromo-2E-acrylic acid (not found); 
3-Hydroxy-3-methyl-glutaric acid (PubChem CID: 1662); 5,7-Dihydroxy-3',4'-dimethoxy-6,8-
dimethylflavone (not found); 5,7-Dihydroxy-3-methoxy-4'-prenyloxyflavone (not found); 5-
Acetylamino-6-formylamino-3-methyluracil (PubChem CID: 108214); alpha-Bromocrotonic 
acid (PubChem CID: 5312952); Apigenin 7-methyl ether 5-glucoside (not found); C16 
Sphinganine (PubChem CID: 70679052); D-Glucoside (PubChem CID: 64947); Di-alpha-
furfuryl ether (PubChem CID: 263034); Emmotin A (PubChem CID: 42608142); Ferulic acid 
(PubChem CID: 445858); Galactopinitol B (PubChem CID: 101926786); gamma-Thujaplicin 
(PubChem CID: 12649); Loganin (PubChem CID: 87691); Methylorsellinic Acid, Ethyl Ester 
(PubChem CID: 3084545); N-hexanoyl-L-Homoserine lactone (PubChem CID: 10058590); 
Oleamide (PubChem CID: 5283387); Oleamide (PubChem CID: 5283387); Oleoside 11-methyl 
ester (PubChem CID: 10692563); Phellodensin D (PubChem CID: 5316782); 
Phlorisobutyrophenone (PubChem CID: 5326317); Phytosphingosine (PubChem CID: 122121); 
Quebrachitol (PubChem CID: 151108); Samidin (PubChem CID: 442150); Sweroside 
(PubChem CID: 161036); Theobromine (PubChem CID: 5429); Undecanedioic acid (PubChem 
CID: 15816). 
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1. Introduction 
Diabetes mellitus refers to a metabolic disorder arising from defects in insulin secretion, insulin 
action or both, resulting in multiple etiology characterized by chronic hyperglycemia and 
disturbances of fat, carbohydrate and protein metabolism (Alberti and Zimmet, 1998). Diabetes 
complications includes heart failure, cardiovascular diseases, adverse drug reactions, infections, 
and early mortality (Thomas et al., 2015).  
Several studies have reported increase in the prevalence of type 2 diabetes in many countries. 
According to Jansson et al. (2015), 382 million people worldwide suffer from diabetes mellitus 
in 2014 and this number has been projected to reach 600 million people by 2035 (Guariguata et 
al., 2014). According to WHO (2016), the global incidence of the disease in adults also increased 
from 108 million in 1980 to 422 million in 2014.  Currently, about 425 million people suffer 
from diabetes globally and 3.1% of this number, representing about 15.9 million people, live in 
Africa (IDF, 2017). As the incidence of the disease increases, so are the associated costs of 
managing the disease, with more impact felt in developing countries where resources are scarce 
(Thomas et al., 2015). Global diabetes-related death was reported to increase from 1.5 million in 
2012 to 1.6 million in 2015, with about 2.2 million deaths attributed hyperglycemia in 2012 
(WHO, 2016). 
Currently available drugs for treating type 2 diabetes include α-glucosidase inhibitors, dipeptidyl 
peptidase-4 (DPP-4) inhibitors, biguanides, sodium glucose transporter 2 inhibitors and 
glucagon-like peptide-1 (GLP-1) receptor agonists. However, challenges such as obvious side 
effects, cost, unavailability in rural areas where they are mostly needed and inability to restore 
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normoglycemia detract hugely from the therapeutic utility and efficacy of these drugs. This also 
motivates interests in developing cheaper, more effective and safer antidiabetic agents. 
Documented evidence for the use of plant extracts or phytochemicals purified from plant-based 
materials is increasing. The greatest success in this regard is the development and current clinical 
use of metformin, isolated from extracts of Galega officinallis, for the treatment of type 2 
diabetes (Bailey and Day, 2004). Anthocleista vogelii Planch, of the Gentianaceae family, is a 
medicinal plant commonly used in West Africa for treating constipation, malaria fever, typhoid 
fever, hypertension and diabetes (Kadiri 2009; Musa et al. 2010; Olubomehin et al., 2013). 
Jiofack et al. (2010) reported the use of A. vogelii stem bark and leaves as a decoction for the 
treatment of diabetes in traditional medicine practice. The aqueous extract of A. vogelii roots has 
been shown to possess hypoglycemic activity both in normal and hyperglycemic mice, rats and 
rabbits (Abuh et al., 1990). In a different study, extracts of the leaves, stem bark and whole root 
of the plant A. vogelii have been shown to modulate α-amylase activities (Olubomehin et al., 
2013) while the methanolic extract of A. vogelii stem bark has been reported to exhibit 
antidiabetic effects in alloxan-induced diabetic rats (Osadebe, 2014). However, mechanisms 
underlying actions of extract of A. vogelii are poorly understood. This study focused on the 
characterization of active constituents of A. vogelii root bark extract and examined its effects on 
activities of enzymes involved in starch digestion in vitro.  Effects of the plant extract on glucose 
tolerance in animals with type 2 diabetes were also assessed.  
 
2. Methodology 
2.1 Plant material 
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Fresh root bark of A. vogelii was harvested in June 2015 from Umuekwune, Ngor-Okpala, Imo 
State, Nigeria. The plant was authenticated by Dr J. O. Ihuma of the Department of Biological 
Sciences, Bingham University, Karu, Nigeria (voucher number GA134-7421) and specimens 
were deposited in Department of Biological Sciences of the University. 
2.2 Preparation of chloroform fraction 
Pulverized dried root bark of A. vogelii (5 kg) was macerated in methanol for 3 days and the 
filtrate was concentrated using rotary evaporator. The methanolic extract (26.5%) was defatted 
by macerating in n-hexane and stirring vigorously at intervals for 24 hrs. The process was 
repeated several times and the n-hexane solution was filtered. The methanolic marc was 
suspended in water and subsequent extraction with chloroform (3x500 ml) by solvent 
partitioning using separating funnel. The chloroform fraction (CF) was concentrated using rotary 
evaporator at 40
o
C to give a percentage yield of 6.7% stored at -20
o
C. A pilot study was 
conducted to investigate effects of the methanolic extract, the n-hexane fraction, chloroform 
fraction and the aqueous fraction on the inhibition of α-amylase and α-glucosidase. Based on the 
results of this preliminary studies (Table S1), CF was selected for further studies.  
2.3 Acute oral toxicity evaluation 
The chloroform fraction of A. vogelii was evaluated for acute oral toxicity in conformity with 
OECD (2002) guidelines. Male Sprague–Dawley rats (200 ±10 g) were randomly selected, 
marked and kept in cages of 5 rats per group. After overnight fasting, rats received a single oral 
administration of chloroform fraction of A. vogelii (300 and 2000 mg/kg body weight) using 
distilled water as vehicle.  Rats were observed for 1, 3 and 14 days respectively for behavioral 
and clinical signs of toxicity. 
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2.4 LC-MS/MS analysis of CF from A. vogelii 
The chloroform fraction of A. vogelli was diluted (10-fold) with methanol and analyzed using 
Agilent 1290 Infinity LC system coupled to Agilent 6520 Accurate-Mass Q-TOF mass 
spectrometer with dual ESI source. The chromatographic separation was carried out using 
Agilent Zorbax Eclipse XDB-C18 column (Narrow-Bore 2.1x150mm, 3.5 micron). The column 
temperature was set at 25⁰C while the Autosampler temperature was 23oCat flow rate of 
0.5ml/min.  Separation was carried out using 0.1% formic acid in water (Solvent A) and 0.1% 
formic acid in acetonitrile (Solvent B). Following sample injection (1µl), both positive and 
negative polarity were run in the ESI-MS experiment for 25 min run and 5 min post run times.  
MS analyses were performed using full scan mode of mass range 100 – 3200 m/z, and 119.03632 
and 966.000725 reference ions. Agilent MassHunter Qualitative Analysis B.05.00 (Method: 
Metabolomics-July2015.m) was used to process the data. The analysis of CF was performed in 
School of Pharmacy, Monash University Malaysia, Selangor, Malaysia. 
 
2.5 Alpha amylase inhibitory assay 
Effects of CF on α-amylase activities was investigated using the starch-iodine test as described 
by Xiao et al, (2006) with slight modifications. The reaction mixture, comprising of 25 µl of 0.02 
M sodium phosphate buffer pH 7.5, 20µl of soluble starch (1%, w/v) and 20µl of either CF or 
acarbose (control), was incubated for 5 min at 37°C in a 96-well microtitre plate. Amylase 
solution (6mg/ml, 15 µl) was added to the reaction mixture and incubated for 15 min at 37°C. 
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This was followed by the addition of 1 M HCl (20μl) to stop the enzymatic reaction. The 
absorbance reading was measured at 620 nm using Synergy HT BioTek
®
 USA microtitre plate 
reader after the addition of 100μl of iodine reagent. The absorbance reading for test samples was 
expressed as a percentage of the absorbance of incubations in the presence of acarbose.  
2.6 Effects of CF on alpha-glucosidase activities  
α-glucosidase activities were measured as described by Johnson et al. (2013). The reaction 
mixture included CF or acarbose (50 µl), 50µl buffer solution (0.1M sodium phosphate buffer, 
pH 6.9) and 100 µl of a 1.0 U/ml α-glucosidase solution in 96 well plate was incubated at 25 °C 
for 10min. Then, 5 mM p-nitrophenyl-α-D-glucopyranoside solution (50 µl) was added to the 
reaction mixture and incubated at 25°C for 5 min. The absorbance was measured at 405 nm 
before initial and after final incubation using Synergy HT BioTek
®
 USA microtitre plate reader. 
The difference between the change in absorbance readings of the sample and control was 
expressed as a percentage of the change in absorbance for control incubations.  
2.7 Induction of obesity-diabetes 
Fifty male Sprague–Dawley rats (30 ± 10 g) were selected from a batch bred within the Animal 
House, Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, 
Pakistan. Animals were maintained with access to food and water ad libitum under controlled 
temperature (23 ± 2°C) and lighting (12:12 h light/dark cycle).  A group of selected rats were fed 
high-fat diet containing 45% kcal fat, 35% kcal carbohydrate and 20% kcal protein for 9 weeks 
prior to experimentation to induce obesity (Ojo et al., 2015). Experimental procedures followed 
the European Community guidelines (EEC Directive of 1986; 86/609/EEC) for animal handling 
and ethical approval number (PHM-0024/EC/M-4-5.15) was given by the Research Ethics 
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Committee of Pharmacy Department, CIIT, Abbottabad. Following a 12 h fast, high-fat fed rats 
included in the study also received a single i.p. injection of 150 mg/kg of freshly prepared 
alloxan in distilled water. Blood glucose concentration was measured 72 h post injection, and 
rats with blood glucose concentration above 300 mg/dl were considered diabetic and separated 
for the studies.  
2.8 Acute in vivo studies  
Acute in vivo dose-dependent effects of CF were examined in overnight fasted non-diabetes rats. 
Rats received a single dose of glucose (18 mmol/kg body weight, i.p.) alone or in combination 
with CF (100 and 200 mg/kg bw) or 10 mg/kg bw glibenclamide (GB). The choice of doses for 
chloroform fraction (CF) of A. vogelii and GB used in this study was informed by literature 
(Osadebe et al., 2014; Okokon et al., 2012) and results of a pilot study conducted. Blood samples 
were collected prior to injection and at 15, 30, 60 and 120 min post injection for measurement of 
glucose concentrations.  
 
2.9 Chronic in vivo studies 
Normal and diabetic rats (n=6) received daily oral administration of either saline vehicle (0.9% 
(w/v), GB (10mg/kg bw) or CF (100 and 200 mg/kg bw) for 21 days. Body weight and non-
fasting blood glucose concentration were measured at the beginning and every 7days during the 
study.  Glucose tolerance (18 mmol/kg body weight, i.p.) was examined in all groups of rat on 
day 21 following an overnight fast as previously described by Irwin et al. (2006).  
 
2.10 Biochemical Analysis 
10 
 
At the end of the study, blood samples were collected by cardiac puncture for measurement of 
serum insulin and leptin concentrations by ELISA (Insulin and Leptin DRG ELISA kits, USA), 
triglycerides (Tietz, 1990), total cholesterol (Trinder, 1969), high density lipoprotein cholesterol 
(Tietz, 1976), and low density lipoprotein cholesterol (Spectrum Diagnostics, Egypt). Insulin 
resistance (IR) was determined by the homeostatic model assessment (HOMA) method as 
described by Matthew et al (1985). HOMA-IR = (insulin (µIU/ml) x glucose (mmol/l))/22.5. 
Visceral fat was isolated from within the abdominal cavity including fat around internal organs 
such as the kidney, liver, intestines and pancreas. Pancreases were excised for histological 
examination. 
2.11 Histopathology 
Excised pancreases were rinsed in distilled water and inserted in 10% neutral buffered formalin 
for histological studies. Tissues were cut into small pieces of not more than 4mm thick and 
inserted into pre-labelled cassettes which were further fixed by immersing in 10% formalin for 
24 hours. Tissue processing and staining with haematoxylin and eosin (H&E) followed 
examination under light microscope (Avwioro, 2010). 
2.12 Statistical Analysis 
Results were presented as the Mean ± S.E.M. One Way ANOVA followed by Tukey’s Multiple 
Range Test was used to determine the statistical significance of difference in parameters amongst 
groups using GraphPad Prism 5. The significant level was taken as P<0.05. 
 
3. RESULTS 
3.1 Acute toxicity study 
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Administration of CF (0 – 2000 mg/kg bw) to normal and diabetic rats produced no adverse 
effect in this study. No death of animals receiving CF was also observed in this study. These 
observations are indicative of lack of acute toxicity for the chloroform fraction of A. vogelii and 
provides justification for the dose of CF used in this study.   
3.2 Chromatographic analysis of CF 
LCMS/MS chromatographic profile of CF from A. vogelii revealed 23 compounds via the 
positive mode (Figure 1A, Table 1). These include three flavonoids ((+)-maackiain 3-O-
glucoside, 5,7-dihydroxy-3',4'-dimethoxy-6,8-dimethylflavone, phellodensin D), three 
carbohydrates (D-glucoside, galactopinitol B, quebrachitol), three terpenes (gamma-thujaplicin, 
loganin, emmotin A), a phenol (phlorisobutyrophenone), a phenolic acid (methylorsellinic acid, 
ethyl ester), two heterocyclic compounds (N-hexanoyl-L-homoserine lactone, samidin) and five 
lipid derivatives (C16 sphinganine, phytosphingosine, undecanedioic acid, oleamide and 3-
hydroxy-3-methyl-glutaric acid). 
Analysis of CF on the ESI-MS run in the negative polarity led to the identification of thirteen 
compounds (Figure 1B, Table 2). These include   two terpenes (oleoside 11-methyl ester, 
sweroside), two flavonoids (apigenin 7-methyl ether 5-glucoside, 5,7-dihydroxy-3-methoxy-4'-
prenyloxyflavone), two heterocyclic compounds (5-acetylamino-6-formylamino-3-methyluracil, 
di-alpha-furfuryl ether); an alkaloid (theobromine), a fatty acyls- lipid (alpha-bromocrotonic 
acid), a phenol (ferulic acid) and an acrylic acid (3-bromo-2E-acrylic acid). 
 
3.3 Effects of CF on α-amylase and α-glucosidase activities 
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In the presence of CF, dose-dependent inhibition of α-amylase activities was also observed.  
Effects produced ranged from 67 to 89% (P<0.05) observed for 1 mg/ml to 10 mg/ml of CF 
respectively (Table S1). Overall, CF had inhibitory activity against α-amylase with IC50 value of 
51.60 ± 0.92 µg/ml compared with the IC50 value of 18.36 ± 0.78 µg/ml recorded for acarbose. 
Results obtained in this study revealed significant reduction in the activities of α-glucosidase in 
the presence of CF or acarbose. CF inhibited α-glucosidase activities by 71% and 82% (P<0.05) 
at 300 µg/ml and 1000 µg/ml respectively (Table S3). The overall α-glucosidase inhibitory 
activity of CF (IC50 = 5.86 ± 0.97 µg/ml) was comparable to acarbose (IC50 = 5.63 ± 1.53 
µg/ml), the standard α-glucosidase inhibitor. 
3.4 Acute effects of CF on glucose tolerance in normal rats 
Similar trend of glucose tolerance was observed in normal rats injected with glucose alone or in 
combination with GB (10mg/kg bw) or CF (100 - 200 mg/kg bw) in this study (Figure 2A).  
Overall effects of glucose, GB or CF administration on plasma glucose concentration, presented 
as area under the curve (AUC 0-120), revealed similar plasma glucose levels in all groups of 
animals (Figure 2B). 
3.5 Sub-chronic effects of CF on body weight, non-fasting blood glucose and glucose in 
diabetic rats  
Average body weight of untreated diabetic rats decreased by 187.4% (P<0.001) compared with 
non-diabetic rats (Figure 3A). Treatment with GB (10mg/kg bw) significantly reduced this 
diabetes-induced weight loss to 64.8% (P<0.05). A similar trend was observed in diabetic-rats 
treated with CF for 21 days with observed weight loss of 42.1% (P<0.05) and 47.8% (P<0.05) 
recorded at CF concentration of 100mg/kg bw and 200mg/kg bw respectively compared with 
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non-diabetic rats. Compared with untreated diabetic rats, CF prevented weight loss by 35% 
(100mg/kg bw, P<0.05) and 26% (200mg/kg bw, P<0.05, Figure 3A). Compared with normal 
rats, significant elevation (P<0.001) of non-fasting blood glucose levels in untreated diabetic rats 
was observed in this study. Gradual reduction of non-fasting blood glucose levels was observed 
in GB treated rats over the period of the experiment (Figure 3B) and the final blood glucose at 
day 21 was similar to the value obtained for normal rats. However, a sharp reduction in non-
fasting blood glucose was observed in diabetic rats treated with CF as from day 7 of treatment 
(Figure 3B).  
Treatment with CF (100 – 200 mg/kg bw) for 21 days significantly improved i.p. glucose (18 
mmol/kg bw) compared to diabetic control rats (Figure 3C, 3D). Compared with rats treated with 
GB (10mg/kg bw) which exhibited an initial rise in blood glucose followed by a sharp reduction 
within 30 mins of administration, the initial sharp rise in blood glucose was prevented in CF-
treated rats. This was followed by a gradual reduction of blood glucose over 120 min (Figure 
3C). Moreover, faster glucose clearance was also observed in CF-treated rats compared with 
non-diabetic rats. Integrated response of CF-treated rats to glucose challenge (AUC120, Figure 
3D) indicated a 128% (P<0.001) and 146% (P<0.001) improvement in glucose tolerance 
compared with untreated diabetic rats. These values are similar to improvement of 132% 
(P<0.001) observed in rats treated with GB (10mg/kg bw). 
3.6 Effects of CF on visceral fat and lipid profile in diabetic rats 
Visceral fat of diabetic control rats were significantly (P<0.05) decreased compared to the non-
diabetic control and the treated groups (Table 3). Visceral fat of rats treated with CF (100 and 
200 mg/kg bw) and GB (10mg/kg bw) were significantly (P<0.05) decreased compared to the 
non-diabetic control. Moreover, rats treated with CF (100 and 200 mg/kg bw) and GB (10mg/kg 
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bw) exhibited significantly (P<0.05) decreased in TG, TC and LDL levels, but significantly 
(P<0.05) increased HDL levels compared to the diabetic and non-diabetic controls. 
 
3.7 Effects of CF-treatment on HOMA-IR, insulin and leptin concentrations in diabetic rats 
Significant reduction in serum insulin concentration was observed in untreated diabetic rats 
(P<0.05, Figure 4A). However, serum insulin concentration in GB-treated (10mg/kg bw) rats 
was 1.25-fold higher compared to untreated rats. A similar increase in insulin concentration was 
in CF-treated rats, with 1.29-fold (P<0.05) and 1.36-fold (P<0.05) observed in rats treated with 
100 mg/kg bw and 200 mg/kg bw of CF respectively. There was significant (P<0.05) increase in 
HOMA-IR in the untreated diabetic rats compared to the normal control (Figure 4B). But rats 
treated with CF (100 and 200mg/kg bw) and GB showed significant (P<0.05) decrease in 
HOMA-IR compared to untreated diabetic rats. The leptin concentrations of rats treated with CF 
(100 and 200 mg/kg bw) were significantly (P<0.05) decreased compared to diabetic control 
(Figure 4C). However, treatment with GB (10mg/kg bw) did not affect leptin concentrations 
compared to both controls. 
3.8 Effects of CF on pancreas histology 
Histology of pancreatic tissue excised from non-diabetic as well as treated and untreated diabetic 
rats are shown in Figures 5(A-E) under X400 magnification. Pancreas parenchyma of non-
diabetic rats showed normal serous acinar and zymogenic cells containing abundant granular 
eosinophilic cytoplasm and normal interlobular connective tissues. There were normal compact 
islets of Langerhans consisting of round to oval collections of endocrine cells (Figure 5A). 
Pancreatic sections of the untreated diabetic rats, on the other hand showed various thickened 
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interlobular connective tissues and degenerated endocrine cells within their islets as well as areas 
indicating necrosis (Figure 5B). Pancreatic sections from glibenclamide-treated rats exhibited 
non-compact islets which appeared diffused without clear margin (Figure 5C). Sections from 
CF-treated (100 and 200 mg/kg) rats were similar to the normal rats (Figure 5B-E)); showing 
pancreatic sections with normal architecture, normal serous acinar and zymogenic cells 
containing abundant granular eosinophilic cytoplasm, normal interlobular connective tissue and 
compact islets consisting of round to oval collections of endocrine cells. 
 
4.0 Discussion 
The chromatographic fingerprint of CF of A. vogelii revealed compounds that have been reported 
to have antidiabetic properties, such as quebrachitol (QCT), loganin, sweroside, oleoside 11-
methyl ester and ferulic acid. Wang et al. (2017) suggested the use of quebrachitol as potential 
antidiabetic agents due to its reported potent glucose-lowering effects and its therapeutic 
application as a β-glucosidase inhibitor is being explored (Rines et al., 2016). Moreover, loganin 
have been reported to ameliorate hyperglycemia in db/db mice (Yamabe et al., 2010; He et al., 
2016) while report of hypoglycemic effects of oleoside 11-methyl ester and ferulic acid are also 
available (Omar, 2010; Ibarra et al., 2009; Ohnishi et al., 2004). Sweroside has been suggested to 
have antidiabetic effect due to its insulin mimicking effect on the regulation of 
phosphoenolpyruvate carboxykinase gene expression (Huang et al., 2016). Sweroside is the only 
compound found in the CF which has been previously isolated from the roots of A. vogelii 
(Chapelle, 1976). Though the collective actions of these phytochemicals may partly account for 
the improved glucose homeostasis observed in CF-treated rats in this study, reports of the action 
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of many of these phytochemicals on insulin secretion, degradation and/or sensitivity, glucose 
tolerance or glucose uptake are generally lacking.  
The observation that glucose tolerance in normal rats injected with a single dose of CF was not 
significantly altered taken together with the sharp reduction in non-fasting blood glucose levels 
in diabetic rats after day 7 suggest that the extract may be slow acting. Moreover, the fact that 
glucose homeostasis is not impaired in the animals used for the acute testing may mask the initial 
effects of CF; which may be minimal. In addition, the fact that non-diabetic rats were used for 
this aspect of the study may also partly explain the absence of acute effects of CF on glucose 
tolerance. On the hand, the result indicated that CF administration within the dose tested in this 
study may not lead to hypoglycaemia, which has been recognized a lethal side effect of some 
currently available antidiabetic drugs (Snyder et al, 2004).  
Animals fed with a high fat diet has been shown to induce characteristic features of obesity and 
type 2 diabetes in mice (Gault et al, 2010; Winzhell and Ahre’n, 2004). Moreover, the 
combination of high-fat feeding with the injection of a chemical agent to induce metabolic 
derangements characterizing type 2 diabetes has also been previously reported (Gault et al., 
2010). Animal models produced via these strategies have become a useful model for the 
investigation of anti-diabetic effects of new therapeutic agents (Ojo et al, 2011; Irwin et al, 2009; 
Abdel-Wahab et al, 2008).  The success of this approach is evident in the marked reduction in 
body weight, significantly elevated non-fasting blood glucose and impaired glucose tolerance 
observed in untreated diabetic animals (Figure 3) in this study.  
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In this study, daily oral administration of CF for 21 days significantly improved glucose 
tolerance. The fact that the body weight loss was prevented in CF-treated animals and that body 
weights of CF-treated animals compare with what was observed for GB-treated animals suggests 
that CF-administration did not produce any unusual adverse effect or affect food intake. 
However, our study showed that prolonged treatment with CF at doses above 100 mg/kg bw may 
lead to hypoglycemic condition. Findings of this study corroborate previous reports of the 
glucose lowering actions of A. vogelii extracts and fractions in diabetic rats (Osadebe et al., 
2014; Sunday et al., 2016; Onyekere et al., 2017) and obese rats (Anyanwu et al., 2013).  
In this study, elevated serum lipids in the untreated diabetic rats was observed. Alloxan-induced 
diabetes in rats is characterized by hyperlipidemia, particularly elevated plasma triglycerides and 
cholesterol levels (Dhandapani et al., 2002). In contrast, the CF-treated and GB-treated rats 
revealed decreased levels of triglycerides, cholesterol and low density lipid cholesterol. These 
indicated beneficial actions of CF in improving lipid profile in treated diabetic rats. Positive 
effects of A. vogelii on the lipid profile status have previously been reported in obese rats 
(Anyanwu et al., 2013). Moreover, alloxan administration has also been reported to induce 
weight loss in rats (Chougale et al., 2007). The reduction of visceral fat in the diabetic rats and 
CF-treated rats might be a reflection of the decreased body weight experienced by those rats. 
Body weight loss in CF-treated rats was lesser compared to weight loss observed in diabetic rats. 
This indicates that CF partially prevented body weight loss as a result of its hypolipidemic and 
hypoglycemic effect. Apigenin 7-methyl ether 5-glucoside, a derivative of apigenin, known for 
its antiobesity properties (Ono and Fujimori, 2011; Guo et al., 2015), was found in CF and may 
have contributed to reduced visceral fat content and body weight observed in this study. Reports 
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of anti-diabetic effects of other phytochemical constituents of CF are lacking in literature. 
Therefore, it is not yet understood if they play a role in the effects observed for CF in this study.  
Diabetic rats had significantly decreased insulin levels which was the reverse in the rats treated 
with 100 and 200 mg/kg bw of CF indicating that CF might have insulinotropic effects. 
Interestingly, insulin levels observed in rats treated with glibenclamide, a sulphonylurea which 
acts via the KATP-dependent pathway to stimulate insulin secretion, were similar to what was 
observed in CF-treated rats. It is known that the observed increase in serum insulin levels could 
result from increased insulin production, secretion or both. This strongly provides a justification 
for the investigation of the insulinotropic actions of CF. Ferulic acid, one of the constituents of 
CF identified in this study, has been previously reported to stimulate increased plasma insulin 
levels in diabetic mice (Jung et al., 2007). According to Jung et al. (2007), ferulic acid also 
regulates blood glucose levels by increasing glucokinase activity and glycogen production in the 
liver. However, it is not yet clear if CF possesses these activities. Previous studies have also 
demonstrated the ability of plant-based materials to signal through the KATP-dependent pathway 
and increase insulin secretion from pancreatic beta cells (Ojo and ojo, 2015). However, it is not 
yet clear if this pathway is involved in the actions of CF. Moreover, beneficial actions of CF may 
also include increase in the proliferation of pancreatic beta cells, leading to increased insulin 
levels in the serum. Therefore, it is important that further studies also investigate actions of CF 
on beta cell proliferation.  
The insulin resistance index, (HOMA-IR), measures insulin sensitivity in clinical and animal 
studies (Sasaki et al., 2009). Since insulin resistance is a characteristic feature of obesity-diabetes 
(Ahmed and Aref, 2010), increased HOMA-IR values observed in the untreated diabetic rats 
establishes insulin resistance as the major morbidity in this model of type 2 diabetes. However, 
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lower HOMA-IR values were observed for the rats treated with the CF (100 and 200mg/kg bw) 
is indicative of the beneficial actions of the plant extract on insulin sensitivity in rats.  Leptin, an 
adipocyte-derived hormone is usually elevated in response to increased body fat mass (Marques 
et al., 2016). High fat feeding produced increased serum leptin levels in non-diabetic control. 
However, serum leptin levels in diabetic control and CF-treated animals were significantly 
reduced. It is suggested that the reduced visceral fat and body weight may play a role in the 
observed effect. Lower leptin levels were observed in CF-treated diabetic rats compared with 
diabetic control rats, which is indicative of the ability of CF to improve leptin sensitivity in rats. 
Histological studies of pancreas isolated from untreated diabetic rats showed areas indicating 
necrosis of beta cells. Beta cells destruction caused by reactive oxygen species generation is a 
morphological feature in alloxan-induced diabetes (Lenzen, 2008). However, the pancreatic 
sections of CF-treated (100 and 200 mg/kg) rats appeared to have normal architecture and 
compact islets. This indicated that CF might have reversed the earlier necrosis of beta cells of 
islets of Langerhans induced by alloxan or enhanced the regeneration of the beta cells. The 
reversal of necrotic actions of alloxan by natural products after the destruction of the beta cells 
has been previously reported (Chakravarthy et al., 1982; Singh and Gupta, 2007). 
The breakdown of complex dietary carbohydrate (starch) to simple sugar (glucose) which can be 
easily absorbed through the small intestine is key function of α-amylase (Kotowaroo et al., 
2006). The inhibition of α-amylase decreases the amount of carbohydrates that could be digested 
and consequently the amount of glucose that enters the bloodstream. Alpha-amylase is not the 
only hydrolysing enzyme of carbohydrate digestion, it is well supported by α-glucosidase, and 
inhibition of both enzyme is key to diabetes management (Wongsa et al., 2012). In this study, 
significant inhibition of α-amylase activities by CF was observed. Similarly, the plant fraction 
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significantly inhibited α-glucosidase activities. While these inhibitory actions may partly explain 
the mechanism underlying the antidiabetic effects of CF, there is a need to fully understand the 
nature of the inhibition. It is known that enzyme inhibitors could mimic an enzyme’s normal 
substrate and compete for the enzyme’s binding site in a reversible or irreversible way (Walsh et 
al, 2007). Inhibitors could also bind to enzyme-substrate complex or bind to the enzyme to 
reduce its activity while not preventing the binding of the normal substrate (Hostettmann et al, 
2006). The exact mechanism involved in the actions of CF observed in this study is not yet 
understood and remains a subject for further studies. Activities α-glucosidase and α-amylase 
were not measured in the diabetic animals treated with CF in this study and future studies to 
clarify the nature of the effects of CF on these enzymes are needed.  
Conclusion 
This study provides scientific evidence for the beneficial actions and traditional use of A. vogelii 
in the management and treatment of diabetes in Africa. More so, it suggests that the antidiabetic 
properties exhibited by the chloroform fraction of A. vogelii may be attributed to constituents of 
the extract previously reported to have antidiabetic activities. Our results suggest that the 
chloroform fraction of A. vogelii might have exerted its antidiabetic properties by increasing 
serum insulin concentration as well as improving the sensitivity of insulin and leptin in obesity-
diabetic rats.  
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LEGEND TO FIGURES 
Figure 1: Chromatographic analysis of chloroform fraction of A. vogelii via positive (A) 
and negative polarity (B). Details of fractions designated by numbers are presented in Table 1 
for A and Table 2 for B.  
 
Figure 2: Acute effects of chloroform fraction of A. vogelii on glucose tolerance in non-
diabetic rats expressed as line graph (A) and area under the curve (B). CF was administered 
to normal rats and glucose concentrations were measured prior to injection and at 15, 30, 60 and 
120 min post-injection.  
 
 
Figure 3: Effects of chronic treatment with chloroform fractions of A. vogelii on body 
weight (A), blood glucose levels (B) and glucose tolerance expressed as line graph (C) and 
area under the curve (D) in diabetic rats. Values are expressed as mean ± SEM with n = 5. 
***P<0.001, **P<0.01, *P<0.05 compared with non-diabetic control rats. 
ΔΔΔ
P<0.001, 
ΔΔ
P<0.01, 
Δ
P<0.05 compared with diabetic control rats.  
 
Figure 4: Effects of chronic treatment with chloroform fractions of A. vogelii on terminal 
serum insulin concentration (A), HOMA-IR (B) and leptin concentration (C) in diabetic 
rats. HOMA-IR: Homeostatic model assessment of insulin resistance. Values are expressed as 
mean ± SEM with n = 5. *P<0.05 compared with non-diabetic control rats.
 Δ
P<0.05 compared 
with diabetic control rats. 
 
 
Figure 5: Chronic treatment with chloroform fractions of A. vogelii on pancreas histology 
in diabetic rats. Tissues were stained with haematoxylin and eosin and image was captured 
under light microscope with X400 magnification. A= Tissue from non-diabetic rats treated with 
saline, B= Tissue from diabetic rats treated with saline, C= Tissue from diabetic rats treated with 
GB (10mg/kg bw) while D and E are tissues from diabetic rats treated with 100 mg/kg bw and 
200 mg/kg bw of CF respectively. All animals were treated for 21 days prior to tissue removal 
for histology. 
 
 
Table 1: Compounds results of the LCMS/MS analysis (positive) of CF of A. vogelii 
 
Table 2: Compounds results of the LCMS analysis (negative) of CF of A. vogelii 
 
 
Table 3: Effects of chloroform fraction of A. vogelii on visceral fat and lipid profile of rats 
TG- Triglycerides, TC- Total cholesterol, HDLC- High density lipoprotein cholesterol, LDLC- low 
density lipoprotein cholesterol. Values are expressed as mean ± SEM with n = 5. Means not sharing 
common letter(s) are significantly different (P < 0.05). 
 
